TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galapagos ( (GLPG) ) has provided an announcement.
On October 30, 2025, Galapagos NV announced significant changes to its Board of Directors to strengthen its strategic focus on business development. The appointments of Dr. Neil Johnston and Devang Bhuva as new directors aim to align the Board’s composition with the company’s strategic direction, enhancing its capacity to execute transformational business development strategies. These changes are expected to support Galapagos in creating value for shareholders and advancing its pipeline of novel medicines.
The most recent analyst rating on (GLPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
Galapagos faces significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. The technical analysis suggests a bearish trend, with potential for a reversal. Valuation metrics are weak due to negative earnings and lack of dividends, further impacting the overall score.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a biopharmaceutical company focused on developing novel medicines to address areas of high unmet medical need. The company is committed to long-term governance and strategic continuity, aiming to enhance its business development efforts and build a robust pipeline of innovative treatments.
Average Trading Volume: 235,562
Technical Sentiment Signal: Sell
Current Market Cap: $2.07B
For detailed information about GLPG stock, go to TipRanks’ Stock Analysis page.